Sec Form 4 Filing - Blobel Friedhelm @ SCICLONE PHARMACEUTICALS INC - 2016-08-12

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Blobel Friedhelm
2. Issuer Name and Ticker or Trading Symbol
SCICLONE PHARMACEUTICALS INC [ SCLN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
President & CEO
(Last) (First) (Middle)
950 TOWER LANE, SUITE 900
3. Date of Earliest Transaction (MM/DD/YY)
08/12/2016
(Street)
FOSTER CITY, CA94404
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/12/2016 M 3,500 A $ 0 463,782 ( 1 ) D
Common Stock 08/12/2016 M 5,000 A $ 0 468,782 D
Common Stock 08/12/2016 M 50,000 A $ 0 518,782 D
Common Stock 08/12/2016 F( 2 ) 1,827 D $ 10.41 516,955 D
Common Stock 08/12/2016 F( 2 ) 26,090 D $ 10.41 490,865 D
Common Stock 08/12/2016 F( 2 ) 2,610 D $ 10.41 488,255 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit ( 3 ) ( 4 ) 08/12/2016 A 40,000 ( 5 ) ( 5 ) Common Stock 40,000 $ 0 383,500 D
Restricted Stock Unit ( 6 ) ( 4 ) 08/12/2016 M 3,500 ( 7 ) ( 7 ) Common Stock 3,500 $ 0 380,000 D
Restricted Stock Unit ( 6 ) ( 4 ) 08/12/2016 M 5,000 ( 8 ) ( 8 ) Common Stock 5,000 $ 0 375,000 D
Restricted Stock Unit ( 6 ) ( 4 ) 08/12/2016 M 50,000 ( 9 ) ( 9 ) Common Stock 50,000 $ 0 325,000 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY, CA94404
X President & CEO
Signatures
Friedhelm Blobel, Ph.D. 08/16/2016
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Includes 1,000 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2016.
( 2 )Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units.
( 3 )Granted under the Issuer's 2015 Equity Incentive Plan.
( 4 )Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
( 5 )Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
( 6 )Granted under the Issuer's 2005 Equity Incentive Plan.
( 7 )Vesting for such RSUs will occur 50% on February 20, 2015 and 50% on February 20, 2016, or on such later date thereafter as the Company's trading window opens if it is not open on either of such dates.
( 8 )Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
( 9 )Vesting to be in three equal annual installments at the close of business on the first business day following December 31 of each of calendar year 2015, 2016, and 2017, provided that the Participant's service with the Company has not terminated prior to the applicable vesting time.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.